Literature DB >> 6330853

Standardization of poliovirus neutralizing antibody tests.

P Albrecht, G van Steenis, A L van Wezel, J Salk.   

Abstract

Recently the Forum for Advancement of Immunization Research sponsored a Collaborative Study on Poliovirus Antibody Titration. Twenty laboratories from 12 countries participated. There were considerable differences in detail of test performance and test results among laboratories. The sensitivity of the tests varied over a 10-fold range (geometric mean titer from 21 to 288). The average coefficient of variation ranged from 4.5% to 13.5%. Tests performed at the Food and Drug Administration indicated that Hep-2 cells were more suitable than Vero cells for poliovirus titration by cytopathic effect end point or plaque assay. However, the cell lines were equally suitable for polio antibody titration by neutralization of cytopathic effect. A high degree of sensitivity and optimal reproducibility of antibody assay were observed in tests utilizing a medium to low dose of virus and serum-virus incubation overnight at 36 C. On the basis of current experience, a protocol is proposed for a test that provides high sensitivity and reproducibility and is practical for large-scale determinations of poliovirus antibody.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6330853     DOI: 10.1093/clinids/6.supplement_2.s540

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  17 in total

1.  Antipoliomyelitis neutralizing antibodies in maternal and neonatal serum.

Authors:  M L Tanzi; P Colotto; M Vignali; P Affanni; U Bracchi; E Bellelli
Journal:  Eur J Epidemiol       Date:  1997-07       Impact factor: 8.082

2.  Antipoliomyelitis immunity status among a population that was regularly vaccinated 11-12 years before.

Authors:  E Bellelli; M L Tanzi; V Bocelli; U Bracchi; P Affanni
Journal:  Eur J Epidemiol       Date:  1991-11       Impact factor: 8.082

3.  Advanced environmental surveillance and molecular analyses indicate separate importations rather than endemic circulation of wild type 1 poliovirus in Gaza district in 2002.

Authors:  Y Manor; S Blomqvist; D Sofer; J Alfandari; T Halmut; B Abramovitz; E Mendelson; L M Shulman
Journal:  Appl Environ Microbiol       Date:  2007-07-27       Impact factor: 4.792

4.  A seroepidemiologic survey of immunity against poliomyelitis in a group of HIV positive and HIV negative drug addicts.

Authors:  F Pregliasco; V Minolfi; A Boschin; A Andreassi; M L Profeta
Journal:  Eur J Epidemiol       Date:  1995-12       Impact factor: 8.082

Review 5.  Clinical development of a new inactivated hepatitis A vaccine.

Authors:  E Vidor; B Fritzell; S Plotkin
Journal:  Infection       Date:  1996 Nov-Dec       Impact factor: 3.553

6.  Immunogenicity and safety evaluation of bivalent types 1 and 3 oral poliovirus vaccine by comparing different poliomyelitis vaccination schedules in China: A randomized controlled non-inferiority clinical trial.

Authors:  Jingjun Qiu; Yunkai Yang; Lirong Huang; Ling Wang; Zhiwei Jiang; Jian Gong; Wei Wang; Hongyan Wang; Shaohong Guo; Chanjuan Li; Shuyuan Wei; Zhaojun Mo; Jielai Xia
Journal:  Hum Vaccin Immunother       Date:  2017-03-01       Impact factor: 3.452

7.  Enzyme-linked immunosorbent assay-based inhibition test for neutralizing antibodies to polioviruses as an alternative to the neutralization test in tissue culture.

Authors:  G Edevåg; B Wahren; A D Osterhaus; V A Sundqvist; M Granström
Journal:  J Clin Microbiol       Date:  1995-11       Impact factor: 5.948

Review 8.  The efficacy of DPT and oral poliomyelitis immunization schedules initiated from birth to 12 weeks of age.

Authors:  N Halsey; A Galazka
Journal:  Bull World Health Organ       Date:  1985       Impact factor: 9.408

9.  Intrathecal immune response and virus-specific immunoglobulin M antibodies in laboratory diagnosis of acute poliomyelitis.

Authors:  M Roivainen; M Agboatwalla; M Stenvik; T Rysä; D S Akram; T Hovi
Journal:  J Clin Microbiol       Date:  1993-09       Impact factor: 5.948

10.  Antigen sparing with adjuvanted inactivated polio vaccine based on Sabin strains.

Authors:  Janny Westdijk; Patrick Koedam; Mario Barro; Benjamin P Steil; Nicolas Collin; Thomas S Vedvick; Wilfried A M Bakker; Peter van der Ley; Gideon Kersten
Journal:  Vaccine       Date:  2013-01-09       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.